미래의 항우울제 : 어떠한 것들이 개발되고 있는가?

키워드

참고문헌 (107)

1. "et al. Cross-national epidemiologyof major depression and bipolar disorder.", pp.293~299 (1996)
2. "Neurobiology of depression.", pp.13~25 (2002)
3. "Recent advances in the neurobiology ofdepression.", pp.6~23 (2002)
4. "The interaction of drug- andpsychotherapy in the long-term treatment of depression.", 62, pp.131~137 (2001)
5. "The clinical psychosocial and pharmacoeconomicramifications of remission.", pp.377~385 (2001)
6. "Clinical guidelines for the treatment of depressive disorders.IV. Medications and other biological treatments.", 46(1), pp.38~58 (2001)
7. ". Overview of antidepressant therapy.", 10, pp.6~9 (2001)
8. "Bupropion:a review of its mechanismof antidepressant activity.", 56, pp.395~401 (1995)
9. "Szegedi A. An overview of theclinical efficacy of mirtazapine.", 1, pp.17~26 (2002)
10. "Venlafaxine:a2003 update.", 25, pp.2138~2154 (2003)
11. "Duloxetine,a dual inhibitor of serotonin and norepinephrine reuptake.", 11, pp.4477~4480 (2003)
12. "Milnacipran and selective serotonin reuptake inhibitors in major depression", 11, pp.41~46 (1996)
13. "A review of theefficacy and tolerability of immediate-release and extended-release formulations of gepirone.", pp.1618~1633 (2003)
14. "Is there a role for 5-HT1A agonistsin the treatment of depression", 53, pp.193~203 (2003)
15. "receptor partial agonist.", pp.1220~1227 (2002)
16. "SB-236057-A^a selective 5-HT1B receptor inverse agonist.", 7, pp.433~444 (2001)
17. "How long should pindolol be associated with paroxetine to improve the antidepressant response?", 17, pp.446~450 (1997)
18. "5-HT1D as well as 5-HT1Aautoreceptors modulate 5-HT release in the guinea-pigdorsal raphe nucleus.", pp.393~402 (1994)
19. "M-100907(Aventis)", 2, pp.123~132 (2001)
20. "Further characterisation of potential", 159, pp.64~69 (2001)
21. "SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety", 41, pp.186~199 (2001)
22. "Serotonin", dopamine interaction--focus on 5-HT2C receptor a newtarget of psychotropic drugs., 2002, pp.40, 1344~1352
23. "Serotonin2C receptor agonists and the behavioural satietysequence in mice.", 71, pp.691~700 (2002)
24. "Anxiolytic-like effects of 5-HT2 ligands on three mouse modelsof anxiety.", 140, pp.203~214 (2003)
25. "5-HT7receptors increase the excitability of rat hippocampalCA1 pyramidal neurons.", 993, pp.230~234 (2003)
26. "SB-258741^a 5-HT7 receptor antagonist ofpotential clinical interest.", 8, pp.90~100 (2002)
27. "5HT7 receptors in the rodent suprachiasmaticnucleus.", 16, pp.19~24 (2001)
28. "Tianeptine:areview of its use in depressive disorders.", 15, pp.231~259 (2001)
29. "Effect of agomelatinein the chronic mild stress model of depressionin the rat.", 28, pp.694~703 (2003)
30. "Effect of two antidepressantdrugs on REM sleep and EMG activity duringsleep.", 39, pp.101~109 (1999)
31. "Tomoxetine(Eli Lilly & Co).", 3, pp.272~277 (2002)
32. "Enhancement of memory consolidation in chicks by beta(3)-adrenoceptor agonists", pp.235~240 (2001)
33. "Sertralineinduced parkinsonism. A case report and an invivostudy of the effect of sertraline on dopamine metabolism.", 105, pp.247~251 (1998)
34. "Double-blind comparative study of the antidepressant unwanted and cardiac effects of minaprine and amitriptyline.", 42, pp.491~498 (1996)
35. "The mesolimbic dopamine system as a targetfor rapid antidepressant action.", 12, pp.12~14 (1997)
36. "Do antidepressants have any potential tocause addiction?", 13, pp.300~307 (1999)
37. "Dopaminergicagents and stimulants as antidepressant augmentationstrategies.", 59, pp.60~63 (1998)
38. "A comparison of paroxetine and amisulpridein the treatment of dysthymic disorder.", 70, pp.313~317 (2002)
39. "A double-blind placebo-controlled trialof the safety and efficacy of selegiline transdermalsystem without dietary restrictions in patients withmajor depressive disorder.", 64, pp.208~214 (2003)
40. "Meta-analysisof the reversible inhibitors of monoamine oxidase typeA moclobemide and brofaromine for the treatment ofdepression.", 20, pp.226~247 (1999)
41. "A reversible monoamine oxidase Ainhibitorstructural approach of its mechanismof action.", 7, pp.1683~1693 (1999)
42. "The impact of early adverseexperiences on brain systems involved in the pathophysiologyof anxiety and affective disorders.", 46, pp.1509~1522 (1999)
43. "Effects of early adverse experiences on brain structureand functionclinical implications.", 48, pp.778~790 (2000)
44. "Depression, stress and the adrenal axis", 15, pp.811~812 (2003)
45. "Corticotropin-releasing hormonereceptor subtypes^emotion.", 46, pp.1480~1508 (1999)
46. "The role of corticotropin-releasing factor in depression and anxiety disorders", 160, pp.1~12 (1999)
47. "Effects of repeated stress on expression of corticotropin releasing factor type I and II receptors", 42, pp.445~453 (2003)
48. "The rationale for corticotropin-releasinghormone receptor antagonists to treat depressionand anxiety.", 33, pp.181~214 (1999)
49. "Effects of the high-affinity corticotropin- releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated", 34, pp.171~181 (2000)
50. "CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors", 93, pp.10477~10482 (1996)
51. "Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress", 65, pp.53~58 (1999)
52. "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1breceptor antagonist suggest an innovativeapproach for the treatment of stress-related disorders.", 99, pp.6370~6375 (2002)
53. "Charney DS. New insights intothe role of cortisol and the glucocorticoid receptor insevere depression.", pp.381~385 (2002)
54. "Depressionduration but not age predicts hippocampalvolume loss in medically healthy women with recurrentmajor depression.", pp.5034~5043 (1999)
55. "The corticosteroid receptor hypothesis ofdepression.", 23, pp.477~501 (2000)
56. "SchatzbergAF. Rapid reversal of psychotic depression usingmifepristone. J Clinical Psychopharmacol 2001", 56. bela(ff jk), pp.516~532
57. "SchatzbergAF. Rapid reversal of psychotic depression usingmifepristone. J Clin Psychopharmacol 2001", 57. bela(ff jk), pp.516~521
58. "Jukic D. Neurokinin receptorsubtypes characterized by biological assays. Life Sci1994", pp.59 2035~2047
59. "60. Saria A. The tachykinin NK1 receptor in the brain", pp.51~60
60. "et al. Distinct mechanism forantidepressant activity by blockade of central substanceP receptors. Science 1998", pp.1640~1645
61. "novel agents in the treatment of depression.", 9, pp.1871~1875 (2000)
62. "Elucidating the antidepressant actions of substance P(NK1 receptor) antagonists", 3, pp.257~261 (2002)
63. "Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associatedwith reduced corticotropin-releasing factor function.", 299, pp.449~458 (2001)
64. "Osanetant Sanofi-Synthelabo", 2, pp.950~956 (2001)
65. "Neuropeptide Y. anatomical distributionand possible function in mammalian nervoussystem. Life Sci 1986", pp.389~401
66. "Neuropeptide Y (NPY) and depression: from animal studies to thehuman condition.", 71, pp.2921~2937 (2002)
67. "Differentialregulation of neuropeptide Y mRNA expression inthe arcuate nucleus and locus coeruleus by stress andantidepressants.", 12, pp.387~395 (2000)
68. "Involvement of hippocampal neuropeptide Y in mediatingthe chronic actions of lithium", 39, pp.1463~1473 (2000)
69. "Mikkelsen JD. Electroconvulsive stimuli enhance bothneuropeptide Y receptor Y1 and Y2 messenger RNAexpression and levels of binding in the rat hippocampus.", 98, pp.33~39 (2000)
70. "The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs", 7, pp.1107~1114 (2002)
71. "Cytokines^the brain^implicationsfor clinical psychiatry", 157, pp.683~694 (2000)
72. "The immune system depression and theaction of antidepressants.", 25, pp.767~780 (2001)
73. "Scharpe S. The monocyte-T-lymphocytehypothesis of major depression.", 20, pp.111~116 (1995)
74. "Inflammatory markers in major depression and melancholia", 63, pp.93~102 (2001)
75. "The role of cytokine network inpsychological stress.", 15, pp.148~155 (2003)
76. "et al. Cytokine-specific centralmonoamine alterations induced by interleukin-1", pp.77 40~49
77. "Regulation of thehuman serotonin transporter by interleukin-1 beta.", 216, pp.560~567 (1995)
78. "Cytokine-serotonin interaction throughIDOA neurodegeneration hypothesis of depression.", 61, pp.519~525 (2003)
79. "The role of cytokines in depression and theirtherapeutic implication.", 11, pp.304~312 (2000)
80. "A novel augmentation strategyfor treating resistant major depression.", pp.131~134 (2001)
81. "BartholiniG. The gabaergic hypothesis of depression. ProgNeuropsychopharmacol Biol Psychiatry 1989", pp.341~351
82. "GABA and affectivedisorders.", pp.159~165 (1987)
83. "Can the antidysphoric and anxiolyticprofiles of selective serotonin reuptake inhibitorsbe related to their ability to increase brain 3 alpha,5alpha-tetrahydroprogesterone availability?", 44, pp.865~873 (1998)
84. "Pagoclone Indevus.", 4, pp.91~95 (2003)
85. "Third generation anticonvulsants inbipolar disorder:a review of efficacy and summary ofclinical recommendations.", 63, pp.275~283 (2002)
86. "Neurosteroids in depression:a review", 165, pp.97~110 (2003)
87. "On the role of metabotropic glutamatereceptors in the mechanisms of action of antidepressants.", 54, pp.581~586 (2002)
88. "interactions with cytokines.", 44, pp.801~809 (2003)
89. "Skolnick P. Glutamate and Depression:Clinicaland Preclinical Studies.", 1003, pp.250~272 (2003)
90. "et al. Antidepressant effects ofketamine in depressed patients.", 47, pp.351~354 (2000)
91. "Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate", 59, pp.1067~1076 (2002)
92. "Spectrum of activityof lamotrigine in treatment-refractory bipolar disorder", 156, pp.1019~1023 (1999)
93. "Use of topiramate a new anti-epileptic as amood stabilizer.", 50, pp.245~251 (1998)
94. "Anxiolytic and side-effect profile of LY354740 highly selective,orally active agonist for groupII metabotropic glutamate receptors.", 284, pp.651~660 (1998)
95. "A molecularand cellular theory of depression.", 54, pp.597~606 (1997)
96. "Regulation ofadult neurogenesis by psychotropic drugs and stress.", 299, pp.401~407 (2001)
97. "Neuroimaging studies of mood disorders.", pp.813~829 (2000)
98. "Chronic antidepressant administrationincreases the expression of cAMP-specific phosphodiesterase4A and 4B isoforms.", 19, pp.610~618 (1999)
99. "Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression", 53, pp.707~742
100. "Increase of bcl-2 protein in neuronal dendriticprocesses of cerebral cortex and hippocampus by theantiparkinsonian drugs, talipexole and pramipexole", pp.236~241
101. "et al. Pramipexole augmentation in thetreatment of unipolar and bipolar depression", 12, pp.137~140 (2000)
102. "Phospholipid metabolism and depression.the possible roles of phospholipase A2 and coenzymeA-independent transacylase.", pp.45~52 (2001)
103. "Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment forrecurrent unipolar depressive disorder.", pp.477~479 (2002)
104. "Horrobin DF. A dose-ranging study of the effectsof ethyl-eicosapentaenoate in patients with ongoingdepression despite apparently adequate treatment withstandard drugs.", 59, pp.913~919 (2002)
105. "Nicotinic acetylcholine receptorsas targets for antidepressants.", pp.106 525~535 (2002)
106. "Antidepressant-like effects of the subtype-selective nicotinicacetylcholine receptor agonist in thelearned helplessness rat model of depression.", pp.295~303 (2000)
107. "De Vry J. Effects of alpha4", beta 2- and alpha 7-nicotine acetylcholine receptoragonists on prepulse inhibition of the acoustic startleresponse in rats and mice., 2002, pp.159, 248~257

관련 논문AI추천